Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196826 | 1.00 | TACR1 (0.57) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL28173714 | 0.99 | TACR1 (0.56) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL28173713 | 0.99 | TACR1 (0.56) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL24113523 | 0.90 | TACR1 (0.57) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL30310544 | 0.90 | TACR1 (0.57) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL1196763 | 0.90 | TACR1 (0.57) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL5116327 | 0.87 | HTR2A (0.54) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL471920 | 0.87 | NPSR1 (0.72) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL6775810 | 0.87 | NPSR1 (0.72) | TACR1SCN9AHTR2AHTR1AHTR2C | |
| SCHEMBL5116320 | 0.87 | HTR2A (0.54) | TACR1SCN9AHTR2AHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-113402438-A | Preparation method of tryptophan derivative medical intermediate | 浙江工业大学 | 2021-09-17 | — | — | CN | disclosed |
| CN-101037437-A | Flazin analog and preparation method and application thereof | KUNMING INST BOTANY CN ACAD (CN) | 2007-09-19 | — | — | CN | disclosed |
| CN-1970559-A | Beta-carboline alkaloid, their preparation method and use | KUNMING INST BOTANY CN ACAD (CN) | 2007-05-30 | — | — | CN | disclosed |
| US-6784179-B2 | treating a vascular disease by administering e.g. tadalafil in combination with an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent such as serotonin | ICOS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6143746-A | Combination of tadalafil and another drug for cGMP-specific PDE inhibition; erectile dysfunction, cardiovascular disorders | ICOS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| CN-1045777-C | Tetracyclic derivatives, preparation method and use | ACOS INC (US) | 1999-10-20 | — | — | CN | disclosed |
| CN-1224720-A | Tetracylic derivatives, process of preparation and use | ICOS CORP (US) | 1999-08-04 | — | — | CN | disclosed |
| US-5859006-A | CYCLIZATION; AMIDATION; SELECTIVE INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATASE SPECIFIC PHOSPHODIESTERASE; USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS; TADALAFIL CLAIMED | ICOS CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
| CN-1143963-A | Tetracyclic derivatives, preparation method and use | GLAXO LAB SA (FR) | 1997-02-26 | — | — | CN | disclosed |
| EP-0740668-A1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | LABORATORIES GLAXO WELLCOME S.A. (FR) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019978-A1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | LABORATOIRES GLAXO WELLCOME S.A. (FR) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | TACR1 976/4885SCN9A 569/4885HTR2A 2985/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | TACR1 3506/4885SCN9A 3898/4885HTR2A 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.